Sunshine State

...i zdravstvenog sistema

Gde je nestao srpski ministar zdravlja? Jeste da je vanredno stanje, pa i ministar odbrane ima svoj role, ali ovo je prvenstveno medicinski problem, pa bi bilo logicno da se i on nekad pojavi...

Jos 3 smrtna slucaja..... ne vidim gde pise koliko je testirano, jer ove ovako gole brojke ne govore mnogo same za sebe.

Pa sve i da imaju pola miliona testiranih i u cifru isti broj zarazenih kao Nemacka, opet imaju duplo vise umrlih od Nemacke

Mislim da sam jednom pisala o holandskom zdravstvu - uopste nisam impresionirana onim sto sam videla za 6 godina tamo, u poredjenju sa nemackim, a mislim da se to ocitava i u ovim brojkama, pa skoro da mogu da kazem da nisam iznenadjena.

Wow!! Nemacka 103,375 zarazenih, 1810 umrlih Holandija 19,580 zarazenih, 2101 umrli Ne uporedjujem Jemen i Dansku, vec dve zapadnoevropske zemlje!

Ima druga tema gde se diskutuje o medicinskom aspektu, i treca o ekonomskom - negde se mora i o politizaciji covid-19

Bas svi? Nesto mi se "javlja" da ce ovi malo poznatiji nekim cudom imati "ozbiljnije simptome" i zahtevati lecenje u redovnim bolnicama

offtopic: samo da se zna da moj smajli nije na vest, vec na Badgerov komentar

The first patients have enrolled in a major late-stage clinical trial testing the arthritis drug Actemra as a potential coronavirus treatment, Business Insider has learned. The study will ultimately enroll 330 people globally and produce initial results in early summer. Participants have to have severe cases of COVID-19, marked by pneumonia and requiring hospitalization. Enrolled patients will randomly receive either an IV infusion of Actemra or a matching placebo. After a month, physicians will assess their clinical status on a seven-category scale to see if they improved or worsened. The trial will help answer if Actemra can provide a real benefit to severe COVID-19 patients, particularly after anecdotal reports of its efficacy have come out of China. So far, at least six patients have been enrolled at trial sites in the US and Spain, Mark Eisner, Genentech's global head of immunology, infectious disease and ophthalmology clinical development, told Business Insider on Monday. Genentech is a subsidiary of Swiss pharmaceutical company Roche. https://www.pmlive.com/pharma_news/fda_approves_roches_actemra_covid-19_trial_1329887

The first Phase I trial for the drug, INO-4800, will involve 40 healthy volunteers. The first dosing is set for today. “Preclinical data, which have been shared with global regulatory authorities and submitted as part of the [investigational new-drug application], have shown promising immune-response results across multiple animal models,” the Plymouth Meeting, Pa., company said in a statement. Each participant in the trial will receive two doses four weeks apart, with results expected by late summer.

Ili privremeni radnici, oni do 90 dana u EU, pa 90 u SRB - takvi sumnjam da imaju neko osiguranje u zemljama u kojima privremeno rade. Ja sam se zajebala, pa dosla na davno planirani put, dok jos nije ni bila frka - frka me zatekla ovde. Imam dodatno privatno nemacko osiguranje, koje me pokriva bilo gde, ali ne daj Boze da mi zatreba lecenje u Srbiji - sasvim sigurno nisam "nagrnula u Srbiju" zbog zdravstvenog sistema.

A ko se takmici? Pokusavamo da razumemo odakle takve cifre kod nas...

To bi trebalo javiti "braci Kinezima" koji savetuju nase strucnjake edit: u Hrvatskoj dosad testirano 11 464, zarazenih 1222, umrlih 16 - znaci nesto preko 11 % testiranih zarazeno; u Srbiji testirano preko 8000, zarazenih 2200

292 nova zarazena, 7 umrlih Kod vas se, izgleda, na svu srecu stisava lagano - svaka cast! p.s. cak i bez policisjkog casa/zatvora!

Ako se neko seca, pisala sam pre desetak dana da je jedna koleginica u UK imala covid-19; pitala sam je da napise kakve je simptome imala, i danas se javila: "It started with a tickle in my throat and then I got an aching in my bones and then headache, then I got the persistent cough and, last, the fever after Day 7. It was never confirmed by tests as UK not testing unless admitted and only admitting after Day 14." Ne pitah je da mi objasni kako su zakljucili da je covid-19, pretpostavljam samo na osnovu simptoma.

Ma i mene taj deo buni/brine - to samo pokazuje ili nedostatak adekvatne terapije, ili zakasnelo reagovanje na simptome ili lose opste zdravlje nasih gradjana

Sumnjam da ce struka dozvoliti jos jedan thalidomide disaster - preskocice se samo ono sto nece (ne sme) kompromitovati safety

Pisao nam CEO regarding COVID-19: We are currently providing monitoring, trial management and safety oversight on both a vaccine and treatment trial for the Division of Microbiology and Infectious Diseases in the US. We have also commenced activities on a 6,000 patient vaccine trial for Pfizer

Da, i po protokolu i to ce potrajati: Participants will be asked to return to the clinic for follow-up visits between vaccinations and for additional visits across the span of a year after the second shot. Clinicians will monitor participants for common vaccination symptoms, such as soreness at the injection site or fever as well as any other medical issues. A protocol team will meet regularly to review safety data, and a safety monitoring committee will also periodically review trial data and advise NIAID. Participants also will be asked to provide blood samples at specified time points, which investigators will test in the laboratory to detect and measure the immune response to the experimental vaccine.

A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine. The vaccine is called mRNA-1273 and was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins

Kako? Pa eno jedan prijatelj, carinik na Horgosu, radio u vreme najvece "najezde" gastarbajtera bez rukavica i zastitne maske - nema, jednostavno nema!

Iz Hrvatske, RAVNATELJ Hrvatskog zavoda za javno zdravstvo Krunoslav Capak: "Mi smo se od samog početka držali smjernica Europskog centra za kontrolu i prevenciju bolesti, kao i Svjetske zdravstvene organizacije. Prvo je rečeno da se testiraju osobe koje su bile u kontaktu s pozitivnom osobom ili su boravile na žarišnim područjima i razvile simptome. Kasnije je ECDC promijenio naputke da treba testirati svaku tešku respiratornu bolest pa onda opet prije 10-ak dana da se testira svaka akutna respiratorna bolest za koju se ne može utvrditi drugi uzrok", rekao je Capak. Ja to nigde ne procitah kod nas...bar ono sto pratim

Grupa 60-69 god 10 puta veca smrtnost kod nas, grupa 40-49 cak 40 puta...uzas

A testiranih? Jer nije isto 284 od 500 i 284 od 1000 Hvala @zoe Bg